Journals / European Journal of Breast Health / 2019 / Cilt: 15 - Sayı: 4

Not Otherwise Specified-Type Sarcoma of Breast with CD10 Expression: Case Report

Pages
268–271
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CD10 expression should be taken intoconsideration in the presence of not diagnosed and not specifid tumors and CD10 should be added to the immunohistochemical panel.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Primary breast sarcomas are very rare and account less than 1% of invasive breast carcinomas.
📊
Key Findings & Data:Recently, a newCD10 positive group of sarcoma was identifid.
💡
Conclusion & Impact:CD10 expression should be taken intoconsideration in the presence of not diagnosed and not specifid tumors and CD10 should be added to the immunohistochemical panel.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Primary breast sarcomas are very rare and account less than 1% of invasive breast carcinomas. Primary sarcomas of breast are leiomyosarcoma, angiosarcoma, liposarcoma, firosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor and pleomorphic sarcoma. Recently, a newCD10 positive group of sarcoma was identifid. Thse tumors cannot be classifid as a soft tissue sarcoma and show diffse strong positive stainingpattern with CD10 (NSCD10). Herein we report clinical and morphological characteristics of two cases diagnosed with not otherwise specifid-typesarcoma with CD10 expression by histologically and immunohistochemical fidings with the literature. NSCD10 shows similarity with leiomyosarcoma and sarcomatoid-type metaplastic carcinoma histomorphologically among specifi sarcomas of breast. CD10 expression should be taken intoconsideration in the presence of not diagnosed and not specifid tumors and CD10 should be added to the immunohistochemical panel.

🔖

Cite This Article

ASLAN, H., BOLAT, F. A., HASBAY, B., AYTAÇ, H. Ö. (2022). Not Otherwise Specified-Type Sarcoma of Breast with CD10 Expression: Case Report. European Journal of Breast Health, Cilt: 15 - Sayı: 4, 268–271. https://ajindex.com/articles/510819

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Leibl S, Moinfar F. Mammary NOS-Type Sarcoma With CD10 Expression. Am J Surg Pathol 2006
  2. (PMID: 16625090) [CrossRef] 2. Sunil R. Lkhani, Ian O, Ellis, Stuart J. S, Puay H. T, Marc J. Van de V, WHO Classifiation of Tumours of the Breast, 2012. 3. Tsai WC, Jin JS, Yu JC, Sheu LF. CD10, Actin and Vimentin Expression in Breast Phylloides Tumors Correlates with Tumor Grades of the WHO Grading System. Int J Surg Pathol 2006
  3. (PMID: 16703173) [CrossRef] 4. Chu P, Arber DA. Paraff section detection of CD10 in 505 nonhematopoetic neoplasms. Am J Clin Patho 2000
  4. (PMID: 10705818) [CrossRef] 5. Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, Caron de Fromentel C, Maguer-Satta V. Th CD10 Enzyme Is a Key Player to Identify and Regulate Human Mammary Stem Cells. Stem Cells 2010
  5. (PMID: 20506111) [CrossRef] 6. Sabah NN, Nazima H, Sohaila F. Mammary Sarcoma- Not Otherwise Specifid: A case Report. Middle East J Cancer 2016
  6. (PMID: 25598952) 7. Kachnar V, Pooja G, Payel D, Pallavi S, Vatsala M. CD10 positive recurrent undiffrentiated mammary sarcoma in a young female: a rare case report with brief review of literatüre. Rare tumors 2015
  7. Yang GZ1, Li J, Jin H, Ding HY. Is mammary not otherwise specifidtype sarcoma with CD10 expression a distinctentity? A rare case report with immunohistochemical and ultrastrucrural study. Diagn Pathol 2013
  8. (PMID: 23356903) [CrossRef] 9. Blanchard DK, Reynolds CA, Grant CS, et al. Primary nonphyloides breast sarcomas. Am J Surg 2003
  9. [CrossRef] 10. Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the mayo Clinic and review of the literatüre. Br J cancer 2004
  10. (PMID: 15187996) [CrossRef]